Overview

Pharmacokinetic Interactions of Metamizole (Dipyrone) in Healthy Subjects

Status:
Completed
Trial end date:
2018-10-31
Target enrollment:
Participant gender:
Summary
Investigators conducted a single center, two-phased, open, controlled pharmacokinetic study to investigate the drug-drug interaction potential of metamizole. For this reason, healthy male volunteers were screened. Enrolled participants were phenotyped on day 1 using the Basel Cocktail (phenotyping cocktail containing specific substrates for CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4). After, they received metamizole treatment for 8 days (3 grams per day). On the 8th day (day 9), they were phenotyped again with the Basel Cocktail and the respective phenotypes (d1 vs. d9) were compared.
Phase:
Phase 1
Details
Lead Sponsor:
University Hospital, Basel, Switzerland
Treatments:
Dipyrone